Valuation: CombiGene AB

Market Cap 4.38Cr 43.69L 38.55L 36.48L 33.08L 62.02L 42Cr 62.63L 1.69Cr 21Cr 1.64Cr 1.6Cr 69Cr P/E 2024
-1.05x
P/E 2025 -3.62x
Enterprise Value 3.79Cr 37.86L 33.41L 31.61L 28.67L 53.74L 36Cr 54.27L 1.46Cr 19Cr 1.42Cr 1.39Cr 60Cr EV / Sales 2024
-13.3x
EV / Sales 2025 128x
Free-Float
53.9%
Yield 2024
8.4%
Yield 2025 88.5%
1 day+1.36%
1 week-4.68%
Current month-3.86%
1 month-3.86%
3 months-0.44%
6 months+8.74%
Current year-0.88%
1 week 2.2
Extreme 2.2
2.3
1 month 2.18
Extreme 2.18
2.42
Current year 1.75
Extreme 1.75
2.6
1 year 1.75
Extreme 1.75
2.87
3 years 1.27
Extreme 1.27
5.9
5 years 1.27
Extreme 1.27
20.05
10 years 1.27
Extreme 1.27
126
Manager TitleAgeSince
Chief Executive Officer 48 31/07/2025
Director TitleAgeSince
Director/Board Member 54 10/12/2024
Chairman 55 11/06/2026
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+1.36%-4.68%-2.61%-61.18% 43.69L
-0.70%-4.28%+52.62%+86.42% 7.15TCr
+0.97%+2.42%+38.69%+83.30% 6.01TCr
-0.48%+2.95%+9.71%+37.55% 4.89TCr
-0.73%-0.41%+48.84%+36.72% 4.43TCr
+1.36%+6.03%+343.85%+638.73% 4.38TCr
-0.47%-0.76%+9.75%+103.07% 4.15TCr
+0.34%+0.22%+5.18%+47.36% 3.01TCr
+4.77%+6.16%+36.77%+26.10% 2.8TCr
-1.73%-4.30%-18.37%+357.94% 2.53TCr
Average +0.44%-0.69%+52.44%+135.60% 3.94TCr
Weighted average by Cap. +0.20%-0.16%+63.34%+147.70%

Financials

2024 2025
Net sales 19.99L 2L 2L 2L 2L 3L 1.92Cr 3L 8L 97.8L 7L 7L 3.15Cr 3L 30.35T 26.78T 25.34T 22.98T 43.09T 29.12L 43.51T 1L 14.87L 1L 1L 47.86L
Net income -4.49Cr -44.8L -39.54L -37.41L -33.93L -63.61L -43Cr -64.23L -1.73Cr -22Cr -1.68Cr -1.65Cr -71Cr -1.24Cr -12.34L -10.89L -10.3L -9L -17.52L -12Cr -17.69L -47.63L -6.05Cr -46.33L -45.32L -19Cr
Net Debt -7.37Cr -73.62L -64.97L -61.48L -55.75L -1.05Cr -71Cr -1.06Cr -2.84Cr -36Cr -2.76Cr -2.7Cr -116.09Cr -58.42L -6L -5L -5L -4L -8L -5.6Cr -8L -22.52L -2.86Cr -21.9L -21.42L -9.2Cr
Logo CombiGene AB
Larkberget AB, formerly Combigene AB, is a Sweden-based company, which is primarily engaged in the healthcare industry. The Company specializes in development of treatments for neurological disorders. The Company's platform comprises the use of gene therapy vectors delivering a combination of transgenes encoding two or more of neuropeptide Y (NPY) receptors, galanin, galanin receptors, somatostatin, and somatostatin receptors, for the treatment of neurological and psychiatric diseases in humans and animals. The Company focuses on the development of an epilepsy treatment by means of an adeno-associated virus (AAV) vector carrying the transgenes for the neurotransmitter NPY and one of its receptors, the G protein-coupled receptor Y2.
Employees
1
Date Price Change Volume
30/26/30 SEK 2.240 +1.36% 7,533
29/26/29 SEK 2.210 -3.91% 1,262
28/26/28 SEK 2.300 +2.22% 537
25/26/25 SEK 2.250 +0.45% 6,565
24/26/24 SEK 2.240 -4.68% 1,442
  1. Stock Market
  2. Stocks
  3. LARK Stock